This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2024 Mar-Apr;27(2):113-115.

doi: 10.4103/aian.aian_328_23. Epub 2023 Jun 12.

Modifying the Collateral Symptoms in Patients with Parkinson's Disease

Shubham Prasad¹, Govind K Makharia¹

Affiliations

PMID: 38751929
PMCID: PMC11093175
DOI: 10.4103/aian.aian_328_23

Editorial

Modifying the Collateral Symptoms in Patients with Parkinson's Disease

Shubham Prasad et al. Ann Indian Acad Neurol. 2024 Mar-Apr.

. 2024 Mar-Apr;27(2):113-115.

doi: 10.4103/aian.aian_328_23. Epub 2023 Jun 12.

Authors

Shubham Prasad¹, Govind K Makharia¹

Affiliation

¹ Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.

PMID: 38751929
PMCID: PMC11093175
DOI: 10.4103/aian.aian_328_23

No abstract available

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

How should we be using biomarkers in trials of disease modification in Parkinson's disease?
Vijiaratnam N, Foltynie T. Vijiaratnam N, et al. Brain. 2023 Dec 1;146(12):4845-4869. doi: 10.1093/brain/awad265. Brain. 2023. PMID: 37536279 Free PMC article.
Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
Schapira AH. Schapira AH. CNS Drugs. 2011 Dec 1;25(12):1061-71. doi: 10.2165/11596310-000000000-00000. CNS Drugs. 2011. PMID: 22133327 Review.
Pharmacological approaches to disease-modifying therapies in Parkinson's disease.
O'Neill MJ, Siemers ER. O'Neill MJ, et al. Expert Rev Neurother. 2002 Nov;2(6):819-34. doi: 10.1586/14737175.2.6.819. Expert Rev Neurother. 2002. PMID: 19810916
[Disease-Modifying Therapy for Parkinson's Disease].
Shimura H, Hattori N. Shimura H, et al. Brain Nerve. 2017 Feb;69(2):159-165. doi: 10.11477/mf.1416200656. Brain Nerve. 2017. PMID: 28202824 Review. Japanese.
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Cilia R, Cereda E, Akpalu A, Sarfo FS, Cham M, Laryea R, Obese V, Oppon K, Del Sorbo F, Bonvegna S, Zecchinelli AL, Pezzoli G. Cilia R, et al. Brain. 2020 Aug 1;143(8):2490-2501. doi: 10.1093/brain/awaa181. Brain. 2020. PMID: 32844196 Free PMC article.

See all similar articles

References

1. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160:99–114.e3. - PubMed
1. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: Impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010;31:938–49. - PubMed
1. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007;69:333–41. - PubMed
1. Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, et al. Medical records documentation of constipation preceding Parkinson disease. Neurology. 2009;73:1752–8. - PMC - PubMed
1. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources